Astrid J Schraa Selected Research

Neoplasms (Cancer)

11/2004	RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward alphavbeta3-expressing endothelial cells.
8/2003	Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin.
12/2002	Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study.
10/2002	Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting.
9/2002	Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug.
2/2002	Ligand-targeted liposomes directed against pathological vasculature.
1/2002	Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Astrid J Schraa Research Topics

Disease

7	Neoplasms (Cancer) 11/2004 - 01/2002
2	Inflammation (Inflammations) 12/2002 - 02/2002
1	Carcinoma (Carcinomatosis) 08/2003
1	Fibrosarcoma 09/2002
1	Neoplasm Metastasis (Metastasis) 09/2002

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 11/2004 - 10/2002
3	Peptides (Polypeptides)IBA 10/2002 - 01/2002
2	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2003 - 09/2002
2	Liposomes (Liposome)IBA 08/2003 - 02/2002
2	IntegrinsIBA 10/2002 - 09/2002
1	liposomal doxorubicin (Doxil)FDA Link 08/2003
1	Angiogenesis InhibitorsIBA 10/2002
1	arginyl-glycyl-aspartic acidIBA 10/2002
1	alanylphenylalanine (Ala-Phe)IBA 09/2002
1	Fibrinolysin FDA Link 09/2002
1	Peptide Hydrolases (Proteases)FDA Link 09/2002
1	ProdrugsIBA 09/2002
1	Integrin beta3 (GPIIIa)IBA 01/2002